Letter to the Editors of Substance Abuse: Research and Treatment; Adolescents Who Vape Nicotine and Their Experiences Vaping: A Qualitative Study; Regarding Dubé et al. (2023).

Autor: Caponnetto P; Center of Excellence for the Acceleration of HArm Reduction (CoEHAR), University of Catania, Catania, Italy.; Department of Educational Sciences, Section of Psychology, University of Catania, Catania, Italy., Triscari S; Department of Educational Sciences, Section of Psychology, University of Catania, Catania, Italy., Vitale NM; Department of Educational Sciences, Section of Psychology, University of Catania, Catania, Italy., Polosa R; Center of Excellence for the Acceleration of HArm Reduction (CoEHAR), University of Catania, Catania, Italy.; Department of Clinical & Experimental Medicine, University of Catania, Catania, Italy.
Jazyk: angličtina
Zdroj: Substance abuse : research and treatment [Subst Abuse] 2023 Sep 12; Vol. 17, pp. 11782218231197959. Date of Electronic Publication: 2023 Sep 12 (Print Publication: 2023).
DOI: 10.1177/11782218231197959
Abstrakt: Competing Interests: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: R.P. is a full tenured professor of Internal Medicine at the University of Catania (Italy) and Medical Director of the Institute for Internal Medicine and Clinical Immunology at the same University. He has received grants from U-BIOPRED and AIR-PROM, Integral Rheumatology & Immunology Specialists Network (IRIS), Foundation for a Smoke Free World, Pfizer, GlaxoSmithKline, CV Therapeutics, NeuroSearch A/S, Sandoz, Merk Sharp & Dohme, Boehringer Ingelheim, Novartis, Arbi Group Srl., Duska Therapeutics, Forest Laboratories, Ministero dell Universita’ e della Ricerca (MUR) Bando PNRR 3277/2021 (CUP E63C22000900006) and 341/2022 (CUP E63C22002080006), funded by NextGenerationEU of the European Union (EU), and the ministerial grant PON REACT-EU 2021 GREEN- Bando 3411/2021 by Ministero dell Universita’’ e (MUR) – —PNRR EU Community. He is the founder of the Center for Tobacco Prevention and Treatment (CPCT) at the University of Catania and of the Center of Excellence for the Acceleration of Harm Reduction at the same university. He receives consultancy fees from Pfizer, Boehringer Ingel- heim, Duska Therapeutics, Forest Laboratories, CV Therapeutics, Sermo Inc., GRG Health, Clarivate Analytics, Guidepoint Expert Network, and GLG Group. He receives textbooks royalties from Elsevier. He is also involved in a patent application for ECLAT Srl. He is a pro bono scientific advisor for Lega Italiana Anti Fumo (LIAF) and the International Network of Nicotine Consumers Organizations (INNCO); and he is Chair of the European Technical Committee for Standardization on “Requirements and test methods for emissions of electronic cigarettes” (CEN/TC 437; WG4). P.C. has been affiliated to the CoEHAR since December 2019 in a pro bono role. He is co-author of 2 papers supported by an Investigator-Initiated Study award program established by Philip Morris International in 2017 and 1 paper supported by grant WS53232647 from GRAND (Global Research Award for Nicotine Dependence), an independently reviewed competitive grants program funded by Pfizer Inc (USA). All other authors have no conflict of interest to declare.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje